IMUX Stock Forecast: Immunic, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Immunic, Inc. is $30. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 19 of 100 as at 18 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Immunic, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (52): The share price has been relatively steady.
Value (15): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
IMUX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IMUX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Oct 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 10 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $22 |
| 10 Sept 2026 | Wedbush | Reiterates | Outperform | $45 |
| 17 Aug 2026 | Wedbush | Initiates | Outperform | $45 |
| 22 May 2026 | B. Riley Securities | Maintains | Buy | $40 → $27 |
| 30 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Apr 2026 | Stifel | Initiates | Buy | — |
| 15 Apr 2026 | D. Boral Capital | Downgrade | Hold | — |
| 24 Mar 2026 | Guggenheim | Initiates | Buy | — |
| 2 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 9 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 14 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 29 Sept 2025 | Chardan Capital | Initiates | Buy | — |
| 26 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 8 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 25 June 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IMUX.
This page is one stock. Monday covers all of them.
IMUX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
IMUX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, Immunic, Inc. returned +3.6% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
IMUX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 2.4×
- EV / EBITDA
- —
Cheaper than 39% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −138.2%
- Return on assets
- −66.8%
- Dividend yield
- —
Higher than 10% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Immunic, Inc. has a market value of $119.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$111.6M.
Free cash flow in the twelve months to 30 June 2026: −$88.0M.
Immunic, Inc. employs 100 people.
Data provided by Twelve Data
IMUX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at IMUX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Immunic, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about IMUX
What is the IMUX stock price forecast for 2026-2027?
The median 12-month analyst price target for Immunic, Inc. is $30, with estimates ranging from $20 to $85. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IMUX stock a buy right now?
Of the 13 analysts covering Immunic, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immunic, Inc. 19 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IMUX?
As at 18 Nov 2026, Immunic, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (52 of 100).
Will IMUX stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts is $30, and Ticker Nerd's factor model ranks Immunic, Inc. 19 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IMUX stock forecast for 2030?
No analyst covering Immunic, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMUX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $85 over the next 12 months.
How has IMUX stock performed over the past year?
Immunic, Inc. returned +3.6% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Immunic, Inc. do?
Immunic, Inc. is a biotechnology company focused on developing selective oral therapies for chronic inflammatory, autoimmune, and neurologic diseases. Its current pipeline centers on small-molecule drug candidates designed to modulate immune activity and improve treatment options for conditions such as multiple sclerosis and ulcerative colitis.
About Immunic, Inc.
Immunic, Inc. is a biotechnology company focused on developing selective oral therapies for chronic inflammatory, autoimmune, and neurologic diseases. Its current pipeline centers on small-molecule drug candidates designed to modulate immune activity and improve treatment options for conditions such as multiple sclerosis and ulcerative colitis. The company’s lead program, IMU-838, is being studied in late-stage and mid-stage clinical development, while IMU-856 is being advanced for gastrointestinal disorders linked to intestinal barrier dysfunction. Immunic also maintains earlier-stage research programs in immune-mediated diseases. With operations in the United States and Germany, Immunic, Inc. plays a role in the clinical-stage biopharmaceutical market by advancing oral, mechanism-based therapies aimed at complex inflammatory conditions.
CEO Mr. Erik Lundgren · 100 employees · United States · https://www.imux.com